http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-112009005072-T5
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f18104b1e55094b717414546db256375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_47b077d73a552d384226bde8ef3c3bf5 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-424 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L1-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-424 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 |
| filingDate | 2009-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e03c36431e8fd57fa0b285333b4776b9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76094a756249cfccf9aaaeb5951f103e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5dbf9031017118ed7831d66f3934c66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1790bbe09766bd0d07636bd1b499303e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a87385e799da0f1f1e1484aa37b7d197 |
| publicationDate | 2012-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | DE-112009005072-T5 |
| titleOfInvention | A process for producing an extract of Gynostaema pentaphyllum having elevated levels of damulin A and damulin B and pharmaceutical compositions thereof for the treatment of metabolic syndrome |
| abstract | Disclosed is an AMPK-activating agent used to alleviate and treat metabolic syndrome, with AMPK (AMP-activated protein kinase) being a major enzyme for regulating an energy sensor and lipid / glucose metabolism in the body. The activation of AMPK inhibits the synthesis of fat and cholesterol and accelerates the reduction of body fat and blood glucose, alleviating obesity, diabetes and hyperlipidemia. The disclosed AMPKaktivierende Stoff contains as active ingredients with alleviating and therapeutic effects on metabolic syndrome including obesity, diabetes and hyperlipidemia, the new compound 2α, 3β, l2β-trihydroxydammar-20 (22) -E, 24-diene-3-O- [β -D-glucopyranosyl- (1 →) -β-D-glucopyranoside], called damulin A ", and the new compound 2α, 3β, 12β-trihydroxy-deammono-20,24-diene-3-O- [β-D- glucopyranosyl- (1 →) -β-D-glucopyranoside], called damulin B. The levels of damulin A and damulin B (as active indicator ingredients for AMPK activation) may be controlled by treating an extract of Gynostaema pentaphyllum at high temperature / high Pressure to be increased. Accordingly, the new extract of Gynostaema pentaphyllum with significantly increased AMPK activation ability can be used to alleviate or treat the metabolic syndrome, such as obesity, diabetes and hyperlipidemia. |
| priorityDate | 2009-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 184.